2004

About Avacta
Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre
CISIONTM platforms.

Avacta Life Sciences has two divisions; therapeutics and diagnostics.

Avacta’s therapeutics division, based in Cambridge, U.K. develops novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre
CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients.

The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.

Avacta’s proprietary pre
CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre
CISIONTM drug candidate, a targeted form of the standard-of-care Doxorubicin, into the clinic by the first half of 2021.

By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies.

Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

The Affimer® platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Therapeutics
Developing the next generation of cancer therapies
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre
CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current cancer immunotherapies as well as current high off-target toxicity experienced by most patients.

Avacta expects to enter the clinic with its lead pre
CISION™ programme, a tumour activated form of doxorubicin, in early 2021. The lead Affimer® programme, a PD-L1 Affimer® antagonist, will form the basis of future bispecifics, combinations with pre
CISION™ chemotherapies and novel tumour microenvironment activated drug conjugates (TMAC®).

Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTx, Inc., a development and commercialisation deal with LG Chem worth up to $310m and a collaboration with ADC Therapeutics to develop novel Affimer® drug conjugates. The Company is actively seeking to license its proprietary platforms in a range of therapeutic areas.

Diagnostics
Development of high performance Affimer®-based diagnostics to improve health outcomes.
Avacta aims to become the leading provider of innovative, next generation diagnostic solutions, and the first choice for disruptive immunodiagnostic products.

Our diagnostics division is utilising our proprietary Affimer® platform to develop AffiDX®in vitro diagnostic (IVD) tests, starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test.

We have also established commercial relationships with IVD companies worldwide to improve the clinical utility of diagnostic testing solutions, by combining bespoke Affimer® reagents with leading diagnostic platform technologies.

Products
AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Affimer® Technology
Affimer® technology is a novel class of biotherapeutic based on a naturally occurring human protein called Stefin A.

Avacta’s proprietary pre
CISION™ technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAP?) which is highly upregulated in the tumour microenvironment of most solid tumours compared with healthy tissues.